Immunicon IPO Proceeds To Support FDA Clearance Of Cancer Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Veridex will stand to benefit from Immunicon's proposed $70.9 mil. IPO under the terms of the companies' exclusive development, licensing and marketing agreement for cancer diagnostics